These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 20966029)

  • 1. Sustained virological response with 29 days of Debio 025 monotherapy in hepatitis C virus genotype 3.
    Patel H; Heathcote EJ
    Gut; 2011 Jun; 60(6):879. PubMed ID: 20966029
    [No Abstract]   [Full Text] [Related]  

  • 2. Interfering with interferon: re-igniting the debate on calcineurin inhibitor choice and antiviral therapy for hepatitis C virus recurrence.
    Watashi K; Metselaar HJ; van der Laan LJ
    Liver Transpl; 2008 Mar; 14(3):265-7. PubMed ID: 18306373
    [No Abstract]   [Full Text] [Related]  

  • 3. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.
    Flisiak R; Horban A; Gallay P; Bobardt M; Selvarajah S; Wiercinska-Drapalo A; Siwak E; Cielniak I; Higersberger J; Kierkus J; Aeschlimann C; Grosgurin P; Nicolas-Métral V; Dumont JM; Porchet H; Crabbé R; Scalfaro P
    Hepatology; 2008 Mar; 47(3):817-26. PubMed ID: 18302285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus genetic variability in patients undergoing antiviral therapy.
    Cristina J; del Pilar Moreno M; Moratorio G
    Virus Res; 2007 Aug; 127(2):185-94. PubMed ID: 17449128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of hepatitis C virus genotype 4.
    Abdo AA; Lee SS
    J Gastroenterol Hepatol; 2004 Nov; 19(11):1233-9. PubMed ID: 15482528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Structure and replication of viral hepatitis C virus, the key of the future therapeutic goals].
    Grigorescu O; Luca CM; Moraru E
    Rev Med Chir Soc Med Nat Iasi; 2008; 112(4):877-81. PubMed ID: 20209756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current therapy of hepatitis C.
    de Knegt RJ
    Scand J Gastroenterol Suppl; 2006; (243):65-9. PubMed ID: 16782624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice.
    McHutchison JG; Bartenschlager R; Patel K; Pawlotsky JM
    J Hepatol; 2006 Feb; 44(2):411-21. PubMed ID: 16364491
    [No Abstract]   [Full Text] [Related]  

  • 10. Implications of finding synergic in vitro drug-drug interactions between interferon-alpha and ribavirin for the treatment of hepatitis C virus.
    Buckwold VE
    J Antimicrob Chemother; 2004 Mar; 53(3):413-4. PubMed ID: 14963071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interferon sensitivity determining region: all hepatitis C virus isolates are not the same.
    Herion D; Hoofnagle JH
    Hepatology; 1997 Mar; 25(3):769-71. PubMed ID: 9049233
    [No Abstract]   [Full Text] [Related]  

  • 12. Alisporivir, a cyclosporin derivative that selectively inhibits cyclophilin, for the treatment of HCV infection.
    Watashi K
    Curr Opin Investig Drugs; 2010 Feb; 11(2):213-24. PubMed ID: 20112171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to direct antiviral agents in patients with hepatitis C virus infection.
    Sarrazin C; Zeuzem S
    Gastroenterology; 2010 Feb; 138(2):447-62. PubMed ID: 20006612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
    Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does iron reduction improve sustained viral responses to interferon monotherapy in hepatitis C patients? Maybe, but is this the right question?
    Shedlofsky SI
    Am J Gastroenterol; 2002 May; 97(5):1093-6. PubMed ID: 12014712
    [No Abstract]   [Full Text] [Related]  

  • 16. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro.
    Paeshuyse J; Kaul A; De Clercq E; Rosenwirth B; Dumont JM; Scalfaro P; Bartenschlager R; Neyts J
    Hepatology; 2006 Apr; 43(4):761-70. PubMed ID: 16557546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy.
    Watashi K; Shimotohno K
    Rev Med Virol; 2007; 17(4):245-52. PubMed ID: 17299803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection.
    Chayama K; Tsubota A; Kobayashi M; Okamoto K; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Suzuki Y; Murashima N; Ikeda K; Kumada H
    Hepatology; 1997 Mar; 25(3):745-9. PubMed ID: 9049229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amino acid substitutions in the nonstructural region 5A of hepatitis C virus genotypes 2a and 2b and its relation to viral load and response to interferon.
    Kobayashi M; Watanabe K; Ishigami M; Murase K; Ito H; Ukai K; Yano M; Takagi K; Hattori M; Kakumu S; Yoshioka K
    Am J Gastroenterol; 2002 Apr; 97(4):988-98. PubMed ID: 12003437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation systems for anti-HCV drugs.
    Moriishi K; Matsuura Y
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1213-21. PubMed ID: 17720275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.